Intracerebral Hemorrhage
Conditions
Keywords
intracerebral hemorrhage, ICH, computed tomography angiography, CTA, recombinant activated factor seven, rFVIIa, NovoSeven, recombinant activated factor VII
Brief summary
The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recombinant activated factor VII (rFVIIa) to placebo to determine the effect of rFVIIa on intracerebral hemorrhage growth.
Detailed description
Intracerebral hemorrhage (ICH)-breakage of a blood vessel with bleeding in the brain-is a devastating form of stroke with a 40-50 percent fatality rate and no proven treatment. Because the majority of deaths from ICH occur within several days of the stroke, interventions for improving outcomes must occur early in the treatment course. Among the potentially modifiable determinants of ICH outcome, hematoma growth is a particularly attractive target for intervention and a major focus of this trial. The purpose of this study is to determine if an imaging test called computed tomography angiography (CTA) can predict which individuals with ICH will experience significant growth in the size of the hemorrhage. Growth of the hemorrhage can cause additional injury and may worsen the outcome. For individuals who are at high risk for hemorrhage growth based on CTA results (i.e., a positive CTA spot sign, evidence of contrast leakage within the hemorrhage), the study will compare the effects of a drug called recombinant activated factor VII (NovoSeven®) or rFVIIa with a placebo to determine which is better for reducing ICH growth. The primary goals of this trial are (1) to determine the sensitivity and specificity of the CTA spot sign for predicting hematoma growth; (2) to determine the feasibility of using CTA to identify individuals with ICH who are at high risk of hematoma growth and to select study participants for randomization to treatment with rFVIIa or placebo; and (3) to determine the rate of hematoma growth among spot-positive individuals at 24 hours-comparing individuals treated with rFVIIa to those treated with placebo. Approximately 184 persons with ICH will be enrolled in one of two study groups at 12 clinical sites across the United States and Canada. Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (CTA spot sign positive) will be randomized to receive either the active study medication, rFVIIa, at 80 mcg/kg, or to receive a placebo (an inactive substance). Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA spot sign negative) will be enrolled into a prospective observational group. Duration of the study for participants is approximately 3 months.
Interventions
Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
DRUGplacebo
An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
University of Cincinnati
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Acute, spontaneous ICH (including bleeding in cerebellum) diagnosed by non-enhanced CT scan within five hours of symptom onset. (Time of onset is defined as the last time the patient was witnessed to be at baseline (i.e., subjects who have stroke symptoms upon awakening will be considered to have their onset at beginning of sleep) * Age \>/= 18 years through 80 years (candidates must have had their 18th birthday, but not had their 81st birthday) * For spot positive patients, dosing of study drug within 90 minutes of enrolling CT scan
Exclusion criteria
* Time of symptom onset of ICH is unknown or more than five hours prior to baseline CT scan, * ICH secondary to known or suspected trauma, aneurysm, vascular malformation, hemorrhagic conversion of ischemic stroke, venous sinus thrombosis, thrombolytic treatment of any condition (e.g., myocardial infarction, cerebral infarction, etc.), central nervous system (CNS) tumor or CNS infection * Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled) * Serum creatinine \> 1.4 mg/dl (123 μmol/L). Sites that currently perform CTA as standard of care for ICH will follow their standard procedures regarding renal insufficiency. * Known allergy to iodinated contrast media * Intravenous or intra-arterial administration of iodinated contrast media within the previous 24 hours of baseline CT scan * Known hereditary (e.g., hemophilia) or acquired hemorrhagic diathesis, coagulation factor deficiency, or anticoagulant therapy with international normalized ration (INR) \> 1.2 * Known or suspected thrombocytopenia (unless current platelet count documented above 50,000 / μl) * Unfractionated heparin use with abnormal partial thromboplastin time (PTT) * Low-molecular weight heparin use within the previous 24 hours * GPIIb/IIIa antagonist use in the previous two weeks * Direct thrombin inhibitor or factor Xa inhibitor within the previous 48 hours * Glasgow Coma Scale score \< 8 at time of proposed enrollment * Pre-admission modified Rankin Scale score \> 2 * Baseline ICH volume of \< 0.5 cc (Hematoma volume will be estimated by local investigators from the baseline CT using the ABC / 2 method.) * Baseline ICH volume of \> 90 cc * Planned surgical evacuation of ICH within 24 hours of symptom onset (placement of intraventricular catheter is not a contraindication to study enrollment.) * Evidence of acute or subacute ischemic stroke on baseline qualifying CT scan * Clinical history of thromboembolism or ischemic vascular disease, including myocardial infarction, coronary artery bypass surgery, cardiac angina, transient ischemic attack, ischemic stroke, peripheral artery disease (vascular claudication), cerebral bypass surgery, carotid endarterectomy, deep venous thrombosis, pulmonary embolism, or coronary or cerebrovascular angioplasty or stenting. (Clinically silent evidence of old ischemia on EKG (Q waves) or CT scan (silent old infarct) will not be considered reasons for exclusion.) * Baseline electrocardiogram shows evidence of acute cardiac ischemia (ST elevation in two contiguous leads, new left bundle branch block (LBBB), or ST depression) * Clinical history suggestive of acute cardiac ischemia (e.g., chest pain) * Abnormal baseline troponin * Females of childbearing potential who are known to be pregnant and/or lactating or who have positive pregnancy tests on admission * Advanced or terminal illness or any other condition the investigator feels would pose a significant hazard to the patient if rFVIIa were administered * Recent (within 30 days) participation in any investigational drug or device trial or earlier participation in any investigational drug or device trial for which the duration of effect is expected to persist until the time of STOP-IT enrollment * Planned withdrawal of care or comfort care measures * Patient known or suspected of not being able to comply with trial protocol (e.g., due to alcoholism, drug dependency or psychological disorder) * Informed consent cannot be obtained from the patient or legally authorized representative
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Specificity of the Spot Sign for Predicting Hematoma Growth | Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours. | The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Specificity was estimated. Specificity or true negative rate is defined as, the number of non-spot positive (spot negative) strokes according to the gold standard / the total number of strokes identified as not spot positive. |
| Number of Study Subjects With Life-threatening Thromboembolic Complications | through day 4 after completion of study drug administration | Thromboembolic complications are defined as development of (1) acute myocardial ischemia; or (2) acute cerebral ischemia; or (3) acute pulmonary embolism |
| Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours. | From baseline to 24 hours | Comparison of only the subjects with a positive spot sign with respect to a categorical measure of hematoma growth from baseline to 24 hours. the outcome of interest is the percent of subjects with hematoma growth \> 33% or \> 6 cc increase in volume, from baseline to 24 hours. |
| The Sensitivity of the Spot Sign for Predicting Hematoma Growth | Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours. | The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as Group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Sensitivity was estimated. Sensitivity or true positive rate is defined as, the number of strokes correctly identified as spot positive according to the gold standard / the total number of strokes identified as spot positive |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes | through day 4 after completion of study drug | Evidence of a deep venous thrombosis or an elevation of troponin within 4 days of completion of study drug administration that are not associated with ECG changes that could be related to the study drug |
| Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score >= 5 | 90 days (+/- 7 days) from time of study enrollment | The modified Rankin Scale (0 is best, 5 is worst - non dead, 6 is dead) was used to define a bad outcome; categorized as a score \>=5 versus \<5. As the aim of the study was to examine the effect of rFIV!!a only the randomized groups, 1 and 2, defined as spot positive by CTA were compared. |
| Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA | Baseline head CT scan within 5 hours, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours. | The CTA was originally interpreted by the site radiologist so that subjects could be identified as having a positive spot sign for eligibility for randomization. The positive spot sign is indicative that there is potential for further hemorrhagic growth and these subjects were thus eligible to be randomized to receive investigational drug or placebo. The CTA scans were subsequently assessed by the study radiologist and compared for agreement. |
| Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)). | 24 hours (+/- 3 hours) from baseline CT scan | Percent change in total volume (intracerebral hemorrhage (ICH) plus intraventricular hemorrhage (IVH)) from baseline CT to 24 hour CT. Percent change is expressed as difference between 24 hour total volume and baseline total volume divided by baseline total volume, expressed as a percentage. In order to examine the effect of rFIVIIa, the randomized groups, Group 1 and Group 2 only were statistically compared. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Group 1 - Randomized to Study Drug Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg). | 10 |
| Group 2 - Randomized to Placebo Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) | 9 |
| Group 3 - Observation Only Arm Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA spot sign negative) will be enrolled into a prospective observational group. | 73 |
| Total | 92 |
Baseline characteristics
| Characteristic | Group 2 - Randomized to Placebo | Total | Group 1 - Randomized to Study Drug | Group 3 - Observation Only Arm |
|---|---|---|---|---|
| Age, Continuous | 62.4 years STANDARD_DEVIATION 12.2 | 61.3 years STANDARD_DEVIATION 11 | 65.4 years STANDARD_DEVIATION 13.1 | 60.7 years STANDARD_DEVIATION 34.7 |
| Glasgow Coma Score/Scale (GCS) | 15 units on a scale | 15 units on a scale | 15 units on a scale | 15 units on a scale |
| Modified Rankin Score (mRS) 0 | 6 Participants | 81 Participants | 10 Participants | 65 Participants |
| Modified Rankin Score (mRS) 1 | 3 Participants | 9 Participants | 0 Participants | 6 Participants |
| Modified Rankin Score (mRS) 2 | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| National Institute of Health Stroke Scale (NIHSS) Score | 12.1 units on a scale STANDARD_DEVIATION 4.9 | 10.9 units on a scale STANDARD_DEVIATION 6 | 14.1 units on a scale STANDARD_DEVIATION 3.9 | 10.3 units on a scale STANDARD_DEVIATION 6.2 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 23 Participants | 1 Participants | 17 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 69 Participants | 9 Participants | 56 Participants |
| Region of Enrollment Canada | 1 Participants | 27 Participants | 3 Participants | 23 Participants |
| Region of Enrollment United States | 8 Participants | 65 Participants | 7 Participants | 50 Participants |
| Sex: Female, Male Female | 3 Participants | 38 Participants | 6 Participants | 29 Participants |
| Sex: Female, Male Male | 6 Participants | 54 Participants | 4 Participants | 44 Participants |
| Time from Stroke to Computed Tomography (CT) Scan | 90.2 minutes STANDARD_DEVIATION 49.9 | 152.9 minutes STANDARD_DEVIATION 80.9 | 158.8 minutes STANDARD_DEVIATION 77 | 159.8 minutes STANDARD_DEVIATION 81.9 |
| Time from Stroke to Study Drug Administration | 181.1 minutes STANDARD_DEVIATION 47.1 | 222.5 minutes STANDARD_DEVIATION 70.4 | 269.9 minutes STANDARD_DEVIATION 68.3 | — |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 10 | 0 / 9 | 4 / 73 |
| other Total, other adverse events | 9 / 10 | 8 / 9 | 65 / 73 |
| serious Total, serious adverse events | 4 / 10 | 4 / 9 | 16 / 73 |
Outcome results
Primary
Number of Study Subjects With Life-threatening Thromboembolic Complications
Thromboembolic complications are defined as development of (1) acute myocardial ischemia; or (2) acute cerebral ischemia; or (3) acute pulmonary embolism
Time frame: through day 4 after completion of study drug administration
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 - Randomized to Study Drug | Number of Study Subjects With Life-threatening Thromboembolic Complications | 1 Participants |
| Group 2 - Randomized to Placebo | Number of Study Subjects With Life-threatening Thromboembolic Complications | 0 Participants |
| Group 3 - Observation Only Arm | Number of Study Subjects With Life-threatening Thromboembolic Complications | 0 Participants |
Comparison: Fisher's exact testp-value: 1Fisher Exact
Primary
Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours.
Comparison of only the subjects with a positive spot sign with respect to a categorical measure of hematoma growth from baseline to 24 hours. the outcome of interest is the percent of subjects with hematoma growth \> 33% or \> 6 cc increase in volume, from baseline to 24 hours.
Time frame: From baseline to 24 hours
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 - Randomized to Study Drug | Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours. | 4 Participants |
| Group 2 - Randomized to Placebo | Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours. | 5 Participants |
| Group 3 - Observation Only Arm | Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours. | 8 Participants |
Comparison: Only the randomized subjects will be comparedp-value: 0.66Fisher Exact
Primary
The Sensitivity of the Spot Sign for Predicting Hematoma Growth
The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as Group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Sensitivity was estimated. Sensitivity or true positive rate is defined as, the number of strokes correctly identified as spot positive according to the gold standard / the total number of strokes identified as spot positive
Time frame: Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group 2 and Group 3.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 - Randomized to Study Drug | The Sensitivity of the Spot Sign for Predicting Hematoma Growth | 4 Participants |
| Group 2 - Randomized to Placebo | The Sensitivity of the Spot Sign for Predicting Hematoma Growth | 5 Participants |
| Group 3 - Observation Only Arm | The Sensitivity of the Spot Sign for Predicting Hematoma Growth | 8 Participants |
p-value: 0.00495% CI: [17.6, 64.6]Fisher Exact
Primary
The Specificity of the Spot Sign for Predicting Hematoma Growth
The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Specificity was estimated. Specificity or true negative rate is defined as, the number of non-spot positive (spot negative) strokes according to the gold standard / the total number of strokes identified as not spot positive.
Time frame: Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group 2 and Group 3.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 - Randomized to Study Drug | The Specificity of the Spot Sign for Predicting Hematoma Growth | 4 Participants |
| Group 2 - Randomized to Placebo | The Specificity of the Spot Sign for Predicting Hematoma Growth | 5 Participants |
| Group 3 - Observation Only Arm | The Specificity of the Spot Sign for Predicting Hematoma Growth | 8 Participants |
p-value: 0.00495% CI: [85.6, 98.1]Fisher Exact
Secondary
Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA
The CTA was originally interpreted by the site radiologist so that subjects could be identified as having a positive spot sign for eligibility for randomization. The positive spot sign is indicative that there is potential for further hemorrhagic growth and these subjects were thus eligible to be randomized to receive investigational drug or placebo. The CTA scans were subsequently assessed by the study radiologist and compared for agreement.
Time frame: Baseline head CT scan within 5 hours, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Overall agreement was assessed but reported by group below.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 - Randomized to Study Drug | Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA | 10 Participants |
| Group 2 - Randomized to Placebo | Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA | 6 Participants |
| Group 3 - Observation Only Arm | Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA | 69 Participants |
95% CI: [0.61, 0.93]
Secondary
Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes
Evidence of a deep venous thrombosis or an elevation of troponin within 4 days of completion of study drug administration that are not associated with ECG changes that could be related to the study drug
Time frame: through day 4 after completion of study drug
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 - Randomized to Study Drug | Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes | 0 Participants |
| Group 2 - Randomized to Placebo | Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes | 1 Participants |
| Group 3 - Observation Only Arm | Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes | 4 Participants |
p-value: 0.47Fisher Exact
Secondary
Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score >= 5
The modified Rankin Scale (0 is best, 5 is worst - non dead, 6 is dead) was used to define a bad outcome; categorized as a score \>=5 versus \<5. As the aim of the study was to examine the effect of rFIV!!a only the randomized groups, 1 and 2, defined as spot positive by CTA were compared.
Time frame: 90 days (+/- 7 days) from time of study enrollment
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 - Randomized to Study Drug | Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score >= 5 | 3 Participants |
| Group 2 - Randomized to Placebo | Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score >= 5 | 1 Participants |
| Group 3 - Observation Only Arm | Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score >= 5 | 6 Participants |
p-value: 0.58Fisher Exact
Secondary
Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)).
Percent change in total volume (intracerebral hemorrhage (ICH) plus intraventricular hemorrhage (IVH)) from baseline CT to 24 hour CT. Percent change is expressed as difference between 24 hour total volume and baseline total volume divided by baseline total volume, expressed as a percentage. In order to examine the effect of rFIVIIa, the randomized groups, Group 1 and Group 2 only were statistically compared.
Time frame: 24 hours (+/- 3 hours) from baseline CT scan
Population: The analysis population consists of 19 subjects diagnosed as Spot Positive on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as Spot Negative on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Group 1 - Randomized to Study Drug | Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)). | 13.51 Percent change from baseline to 24 hours |
| Group 2 - Randomized to Placebo | Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)). | 20.96 Percent change from baseline to 24 hours |
| Group 3 - Observation Only Arm | Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)). | 5.12 Percent change from baseline to 24 hours |
Comparison: Groups 1 and 2 only the spot positive subjects randomized to interventional drug or placebop-value: 0.25Kruskal-Wallis